Search - tctmd.com

Displaying 121 - 140 of 234

Sort: Relevancy | Date

Presentation TCT 2014

TCT 404: First Clinical Experience with Neurotropic Agents for Treatment of Sympathetic Hypertension

Presenter: Michael R. Jaff, Horst Sievert, Michael J. Rinaldi

September 14, 2014

Presentation TCT 2014

Resistant Hypertension!

Presenter: Atul Pathak

September 14, 2014

Presentation TCT 2014

Early Stage or Uncontrolled Hypertension!

Presenter: Darrel P. Francis

September 14, 2014

Presentation TCT 2014

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Antonios Karanasos

September 14, 2014

Presentation TCT 2014

Updates and Status of the Cordis Renlane Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Felix Mahfoud

September 14, 2014

Presentation TCT 2014

Updates and Status of the ReCor Paradise Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Thomas Zeller

September 14, 2014

Presentation TCT 2014

Going to the Source: Early Clinical Results with the Afferently Directed Nonvascular Renal Denervation System (Verve Medical)

Presenter: Frank Litvack, Richard R. Heuser

September 14, 2014

Presentation TCT 2014

Updates and Status of the St. Jude EnligHTN Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Updates and Status of the Boston Scientific Vessix Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Daily News

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

Caitlin E. Cox

June 24, 2014

News Features

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

June 24, 2014

News Daily News

CABG Mejor que PCI en Pacientes a Diálisis con Enfermedad Coronaria Compleja

Caitlin E. Cox

June 24, 2014

Presentation

PCI vs CABG in Patients with End-Stage Renal Disease Requiring Dialysis

Presenter: Akira Marui

June 20, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

Advertisement

TCT 404: First Clinical Experience with Neurotropic Agents for Treatment of Sympathetic Hypertension

Resistant Hypertension!

Early Stage or Uncontrolled Hypertension!

TCT 406: Renal Artery Trauma Induced by Four Different Renal Denervation Systems: A Multimodality Intraarterial Imaging Study

Updates and Status of the Cordis Renlane Program

Updates and Status of the ReCor Paradise Program

Going to the Source: Early Clinical Results with the Afferently Directed Nonvascular Renal Denervation System (Verve Medical)

Updates and Status of the St. Jude EnligHTN Program

Updates and Status of the Boston Scientific Vessix Program

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Dialysis Patients with Complex Coronary Disease Fare Better at 5 Years with CABG vs PCI

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

CABG Mejor que PCI en Pacientes a Diálisis con Enfermedad Coronaria Compleja

PCI vs CABG in Patients with End-Stage Renal Disease Requiring Dialysis

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content